Clinical Trial Search

Primary: Percentage of Participants Who Achieved Success Rate 0 (Clear) or 1 (Almost Clear) on the Investigator Global Assessment (IGA) Scale at Week 12 (Last Observation Carried…

Primary: Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population — 67; 64; 21; 27 Participants

Primary: Pain Felt During the Procedure — 0.29; 0.30 score on a scale

Primary: Maximum Observed Serum Concentration (Cmax) of Romosozumab — 2.64; 1.74; 13.8; 10.3 μg/mL

Primary: Self-reported Abstinence From Alcohol — 9.44; 0.32 percentage of participants

Primary: Number of MII Oocytes Retrieved Between the Two Arms — 4.1; 3.0 number of oocytes

Primary: Clinical Improvement — 8 Participants

Primary: Change From Preoperative Baseline in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS Part III) "Off" Medications — -16.90322581…

Primary: Recommendations for Cancer Surveillance (Patient-reported Outcomes From the Survivor Self-Assessment) — 93 % of pts w/accurate TS for primary site

Primary: Percentage of Participants With ≥1 Solicited Injection-site Adverse Events — 54.4; 57.9; 50.9; 59.6 Percentage of Participants

Primary: AUC0-6h of Pain Intensity Between Time 0 (Baseline Value of VAS) and 6 Hours Post-treatment in the ITT Population. — 5031; 7593 mm*min — p=0.020

Primary: Phase Ia: Number of Patients With DLTs Observed in the First Cycle — 0; 0; 0; 0 Participants

Primary: Number of Participants Who Achieved Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) at Month 6: Tofacitinib Overall Versus TNFis Overall…

Primary: Rate and Severity of Falls (Calculated With an Algorithm) — 2; 2 score on a scale

Primary: Percentage of Participants With an Overall Score of ≤ 4 on the FCCHL Scale. — 518; 468 Participants